Study has indicated that the pyruvate kinase muscle isozyme (PKM2) inhibitor suppresses glycolysis and the differentiation of Th1 and Th17, thereby reducing disease activity and alleviating experimental autoimmune encephalomyelitis (EAE) by inhibiting PK activity (58). This evidence concerns the gene PKM and experimental autoimmune encephalomyelitis.